Literature DB >> 16072

Expression of endogenous murine leukemia viruses during the course of a protracted immunological disorder.

M Y Armstrong, N H Ruddle, F F Richards.   

Abstract

Mice of the low leukemia (BALB/cJ x A/J)F1 hybrid (CAF1) strain express B-and N-tropic infectious murine leukemia virus (MuLV) after the age of 6 mo. Initation of a protracted immunological disorder, the graft-versus-host reaction (GVHR), at 7 wk of age, accelerates the induction of both these mouse-tropic endogenous viruses, and preferentially enhances the replication of B-tropic MuLV. The earlier appearance of B-tropic MuLV in a greater proportion of mice and in higher titer is thought to be casually related to the eventual development of lymphoreticular tumors in the GVHR mice, since previous studies have shown that these same tumors can be reproduced by inoculating syngeneic recipients with serially passaged GVHR extracts containing B-tropic MuLV.

Entities:  

Mesh:

Year:  1977        PMID: 16072      PMCID: PMC2180637          DOI: 10.1084/jem.145.4.1060

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Dependence of Moloney murine leukemia virus production on cell growth.

Authors:  M P Paskind; R A Weinberg; D Baltimore
Journal:  Virology       Date:  1975-09       Impact factor: 3.616

2.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

3.  Role of endogenous murine leukemia virus in immunologically triggered lymphoreticular tumors. I. Development and use of oncogenic cellfree preparations serially passaged in vivo.

Authors:  M Y Armstrong; N H Ruddle; M B Lipman; S K Pierce; F F Richards
Journal:  J Natl Cancer Inst       Date:  1977-01       Impact factor: 13.506

4.  Murine C-type RNA virus from spontaneous neoplasms: in vitro host range and oncogenic potential.

Authors:  R L Peters; G J Spahn; L S Rabstein; G J Kelloff; R J Huebner
Journal:  Science       Date:  1973-08-17       Impact factor: 47.728

5.  Xenotropic viruses: murine leukemia viruses associated with NIH Swiss, NZB, and other mouse strains.

Authors:  J A Levy
Journal:  Science       Date:  1973-12-14       Impact factor: 47.728

6.  Prevalence of the group-specific (gs) antigen and infectious virus expressions of the murine C-type RNA viruses during the life span of BALB-cCr mice.

Authors:  R L Peters; J W Hartley; G J Spahn; L S Rabstein; C E Whitmire; H C Turner; R J Huebner
Journal:  Int J Cancer       Date:  1972-09-15       Impact factor: 7.396

7.  Replication of murine leukemia virus in bone marrow-derived lymphocytes.

Authors:  N H Ruddle; M K Armstrong; F F Richards
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

8.  Tumor induction by immunologically activated murine leukemia virus.

Authors:  M Y Armstrong; N H Ruddle; M B Lipman; F F Richards
Journal:  J Exp Med       Date:  1973-05-01       Impact factor: 14.307

9.  A major genetic locus affecting resistance to infection with murine leukemia viruses. I. Tissue culture studies of naturally occurring viruses.

Authors:  T Pincus; J W Hartley; W P Rowe
Journal:  J Exp Med       Date:  1971-06-01       Impact factor: 14.307

10.  Quantitative studies of naturally occurring murine leukemia virus infection of AKR mice.

Authors:  W P Rowe; T Pincus
Journal:  J Exp Med       Date:  1972-02-01       Impact factor: 14.307

View more
  2 in total

1.  Endogenous RNA tumor viruses are activated during chemical induction of murine plasmacytomas.

Authors:  M Y Armstrong; P Ebenstein; W H Konigsberg; F F Richards
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

2.  Expression of endogenous xenotropic retrovirus by methylcholanthrene-induced squamous cell carcinoma of the mouse respiratory tract.

Authors:  P Ebenstein; B Kinder; D O Bankole; F F Richards; M Y Armstrong
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 17.579

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.